Loading...
Loading...
Contributors:
Dataset URI:
10.3389/fimmu.2026.1805471.s001BackgroundGastric cancer is a leading cause of cancer-related mortality, with limited efficacy of immunotherapies due to intratumoral heterogeneity, an immunosuppressive microenvironment, and antigen-loss escape. The optimization of chimeric antigen receptor (CAR) T-cell therapy targeting PD-L1 and Claudin18.2 (CLDN18.2) is crucial for improving the antitumor response.MethodsWe performed a stepwise optimization of CAR designs targeting PD-L1 and CLDN18.2, focusing on the costimulatory domains and intracellular signaling architecture. We engineered monospecific PD-L1 and CLDN18.2 CAR-T cells using CD28 or 4-1BB costimulatory domains and assessed their CAR expression, activation phenotype, subset composition, and cytotoxicity. We then engineered three bicistronic dual-target CARs with distinct CD3ζ configurations and evaluated their functionality through in vitro assays and in vivo NUGC4-Luc gastric cancer xenograft models.ResultsThe single-target CLDN18.2-CD28 CAR-T cells exhibited the strongest cytotoxicity in vitro. Among the bicistronic designs, the double-CD3ζ CAR-T cells showed superior expansion, differentiation, and cytotoxicity compared to alternative bicistronic constructs and single-target CAR-T cells. Bulk RNA sequencing revealed enhanced immune activation and reduced exhaustion markers in the double-CD3ζ CAR-T cells. In the NUGC4-Luc xenograft model, the double-CD3ζ CAR-T cells achieved a tumor growth inhibition of 63.23%, outperforming the 48.06% inhibition observed with single CLDN18.2 CAR-T cells.ConclusionsThe study identifies a bicistronic dual-target, double-CD3ζ CAR-T design that enhances T-cell functional fitness and antitumor efficacy in gastric cancer models. This approach offers a promising strategy for addressing antigen heterogeneity and improving the durability of CAR-T therapies in solid tumors.
Keyword(s):
bicistronic CAR; CAR T-cell therapy; CD3ζ; CLDN18.2; dual-target CAR-T.
MeSH Term(s):
Grants and Funding:
No Grants or Funding Data Available
Associated Publication(s):
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)